Aranesp® (darbepoetin alfa) — Total revenues
Amgen Aranesp® (darbepoetin alfa) — Total revenues decreased by 6.6% to $311.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.5%, from $340.00M to $311.00M. Over 3 years (FY 2022 to FY 2025), Aranesp® (darbepoetin alfa) — Total revenues shows relatively stable performance with a -0.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market demand or effective pricing strategies, while a decrease may indicate market share erosion due to competition or a decline in clinical usage.
Detailed definition
This metric represents the total gross sales generated from the Aranesp product line, a therapeutic agent used to treat...
Peer comparison
Comparable to product-specific revenue reporting for mature biologic or specialty pharmaceutical assets at peer biotechnology companies.
amgn_segment_aranesp_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $367.00M | $396.00M | $358.00M | $357.00M | $358.00M | $348.00M | $355.00M | $365.00M | $323.00M | $319.00M | $349.00M | $348.00M | $337.00M | $308.00M | $340.00M | $359.00M | $357.00M | $333.00M | $311.00M |
| QoQ Change | — | +7.9% | -9.6% | -0.3% | +0.3% | -2.8% | +2.0% | +2.8% | -11.5% | -1.2% | +9.4% | -0.3% | -3.2% | -8.6% | +10.4% | +5.6% | -0.6% | -6.7% | -6.6% |
| YoY Change | — | — | — | -2.7% | -9.6% | — | -0.8% | +2.2% | -9.8% | -8.3% | -1.7% | -4.7% | +4.3% | -3.4% | -2.6% | +3.2% | +5.9% | +8.1% | -8.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's aranesp® (darbepoetin alfa) — total revenues?
- Amgen (AMGN) reported aranesp® (darbepoetin alfa) — total revenues of $311.00M in Q1 2026.
- How has Amgen's aranesp® (darbepoetin alfa) — total revenues changed year-over-year?
- Amgen's aranesp® (darbepoetin alfa) — total revenues decreased by 8.5% year-over-year, from $340.00M to $311.00M.
- What is the long-term trend for Amgen's aranesp® (darbepoetin alfa) — total revenues?
- Over 3 years (2022 to 2025), Amgen's aranesp® (darbepoetin alfa) — total revenues has grown at a -0.8% compound annual growth rate (CAGR), from $1.42B to $1.39B.
- What does aranesp® (darbepoetin alfa) — total revenues mean?
- The total revenue generated from sales of the Aranesp therapeutic product.